Classification of GBA Variants and Their Effects in Synucleinopathies
Mov Disord
.
2019 Oct;34(10):1581-1582.
doi: 10.1002/mds.27803.
Authors
Ziv Gan-Or
1
2
3
,
Roy N Alcalay
4
5
,
Mary B Makarious
6
,
Sonja W Scholz
6
,
Cornelis Blauwendraat
7
;
International Parkinson's Disease Genomics Consortium (IPDGC)
Affiliations
1
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
2
Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.
3
Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
4
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
5
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
6
Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
7
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
PMID:
31769092
DOI:
10.1002/mds.27803
No abstract available
Publication types
Letter
Comment
MeSH terms
Glucosylceramidase / genetics*
Humans
Lewy Body Disease*
Mutation
Synucleinopathies*
alpha-Synuclein
Substances
alpha-Synuclein
Glucosylceramidase
Grants and funding
J-1101/PUK_/Parkinson's UK/United Kingdom